Objective

• As a continuation of the prior research study which confirmed biofield therapy’s antitumor and antimetastatic efficacy and mechanism in cancer invitro, the second phase is to further investigate efficacy and mechanism invivo, as well as to further investigate the nature of the biofield healing signal through blocking, distance, EEG, and quantum entanglement studies

Hypothesis

• Biofield therapy reduces xenograft tumorigenesis (tumor formation) and metastases (tumor spread) across a number of cancer types invivo to a greater extent than conventional treatment.  This will be detectable not only through tumor remission/reduction but also via various biological markers
• Biofield therapy functions by modulating oncogenic pathways, their downstream targets, and the tumor microenvironment
• Biofield therapy is mediated by electromagnetic frequencies, gauged by whether EMF shielding attenuates the biofield healing effect
• A second biofield therapist will have similar efficacy outcomes in select invitro and invivo animal models, demonstrating a generalizable effect across biofield therapists

Outcomes

• In replicating the prior biofield therapy experiments, confirmed efficacy of biofield therapy with antiproliferative effects and antimetastatic effects across 6+ types of pancreatic cells and in 2 types of mice:
  • Reducing the growth rate of tumor statistically significantly relative to controls
  • Inhibiting migration and invasion in pancreatic cells statistically significantly relative to controls, with metastasis reduced by 34-55% in cells and 51-73% in animals, stopping cell cycle progression early and dramatically decreasing spread to surrounding cells better than today’s standard of care drug, gemcitabine
• Determined biochemically mediated mechanisms of action of biofield therapy on pancreatic cancer invitro and invivo observing:
  • Altered cellular and mitochondrial structure, which may be one physical cause inhibiting spread
  • Modulated expression of FOXM1, a protein that binds to genes to control their activity, which suggests that the biofield therapy-induced anti-metastatic effect may be at least in part mediated by its ability to downregulate the FOXM1 protein
  • Altered cell voltage membrane potential, as evidenced in the membrane itself and the ion channels in the cell wall which control the movement of electrons through the barrier, which appears to be upstream of and perhaps controlling the aforementioned biochemical shifts
  • Altered immune cell profile in mice, turning on the immune function to kill cancer cells
• Replicated the results with a second biofield therapist invitro and in invivo animal models with consistent outcomes
• Evaluated whether biofield therapy is mediated by electromagnetic frequencies (EMFs) with EMF shielding and distance experimentation with no blocking or attenuation of effect.
• Observed correlated healer EEG and pancreatic cell-level signaling, in a way that suggests bidirectional informational exchange/influence, perhaps a form of entanglement which requires further research in the subsequent stage

Publication in Biophysica:

Search for Entanglement between Spatially Separated Living Systems: Experiment Design, Results, and Lessons Learned

Publication in Nature’s Scientific Reports

Examining the effects of biofield therapy through simultaneous assessment of electrophysiological and cellular outcomes

Further publications are in process